F10 and COVID-19: In the absence of a prospective, double-blind randomized clinical trial comparing the direct and indirect inhibitors of FXa in COVID-19 patients, these in vivo results with live SARS-CoV-2 provide preclinical support for using an indirect FXa inhibitor such as FONDA as an anticoagulant when attempting to prevent or treat thrombotic complications of COVID-19.